Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 22665-22667 [05-8746]

Download as PDF Federal Register / Vol. 70, No. 83 / Monday, May 2, 2005 / Notices ACTION: Notice. The Food and Drug Administration (FDA) is announcing the availability of a draft document entitled ‘‘Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials,’’ dated April 2005. The draft guidance provides sponsors of vaccine trials with recommendations on assessing the severity of clinical and laboratory abnormalities in healthy adult and adolescent volunteers enrolled in clinical trials. In particular, the draft guidance includes toxicity grading scale tables to use as a guideline for selecting the assessment criteria. DATES: Submit written or electronic comments on the draft guidance by August 1, 2005 to ensure their adequate consideration in preparation of the final guidance. General comments on agency guidance documents are welcome at any time. ADDRESSES: Submit written requests for single copies of the draft guidance to the Office of Communication, Training, and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448. Send one self-addressed adhesive label to assist the office in processing your requests. The draft guidance may also be obtained by mail by calling the CBER Voice Information System at 1–800–835–4709 or 301–827–1800. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document. Submit written comments on the draft guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to https:// www.fda.gov/dockets/ecomments. FOR FURTHER INFORMATION CONTACT: Brenda R. Friend, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448, 301–827–6210. SUPPLEMENTARY INFORMATION: SUMMARY: selecting the criteria to assess the severity of clinical and laboratory abnormalities in healthy adult and adolescent volunteers enrolled in clinical trials. The parameters in the tables are not necessarily warranted for every clinical trial of healthy volunteers. The parameters monitored should be appropriate for the specific study vaccine. In addition, the use of toxicity grading scales to categorize adverse events observed during clinical trials does not replace regulatory requirements to monitor, investigate, and report adverse events. The draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the agency’s current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirement of the applicable statutes and regulations. II. Comments The draft guidance is being distributed for comment purposes only and is not intended for implementation at this time. Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding the draft guidance. Submit written or electronic comments to ensure adequate consideration in preparation of the final guidance. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in the brackets in the heading of this document. A copy of the draft guidance and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. III. Electronic Access I. Background FDA is announcing the availability of a draft document entitled ‘‘Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials’’ dated April 2005. The draft guidance provides sponsors of vaccine trials with toxicity grading scale tables as a guideline for Persons with access to the Internet may obtain the draft guidance at either https://www.fda.gov/cber/guidelines.htm or https://www.fda.gov/ohrms/dockets/ default.htm. Dated: April 22, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 05–8634 Filed 4–29–05; 8:45 am] VerDate jul<14>2003 19:05 Apr 29, 2005 Jkt 205001 BILLING CODE 4160–01–S PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 22665 DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at https://workplace.samhsa.gov and https://www.drugfreeworkplace.gov. FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276– 2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. Subpart C of the Mandatory Guidelines, ‘‘Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,’’ sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that E:\FR\FM\02MYN1.SGM 02MYN1 22666 Federal Register / Vol. 70, No. 83 / Monday, May 2, 2005 / Notices certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards. In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens: ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414– 328–7840/800–877–7016, (Formerly: Bayshore Clinical Laboratory). ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264. Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794– 5770/888–290–1150. Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615–255–2400. Baptist Medical Center-Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501– 202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800– 445–6917. Diagnostic Services Inc., dba DSI, 12700 Westlinks Dr., Fort Myers, FL 33913, 239–561–8200/800–735– 5416. Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229– 671–2281. DrugProof, Division of Dynacare/ Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206–386–2661/800–898–0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.). DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215–674–9310. Dynacare Kasper Medical Laboratories,* 10150–102 St., Suite 200, Edmonton, Alberta, Canada T5J 5E2, 780–451–3702/800–661–9876. ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 662– 236–2609. VerDate jul<14>2003 19:05 Apr 29, 2005 Jkt 205001 Express Analytical Labs, 3405 7th Ave., Suite 106, Marion, IA 52302, 319– 377–0500. General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608–267–6225. Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504– 361–8989/800–433–3823. (Formerly: Laboratory Specialists, Inc.). LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/ 800–873–8845. (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.). Laboratory Corporation of America Holdings, 7207 N. Gessner Rd., Houston, TX 77040, 713–856–8288/ 800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437– 4986. (Formerly: Roche Biomedical Laboratories, Inc.). Laboratory Corporation of America Holdings, 1904 Alexander Dr., Research Triangle Park, NC 27709, 919–572–6900/800–833–3984. (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group). Laboratory Corporation of America Holdings, 10788 Roselle St., San Diego, CA 92121, 800–882–7272. (Formerly: Poisonlab, Inc.). Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827– 8042/800–233–6339. (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center). Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715–389–3734/800–331–3734. MAXXAM Analytics Inc.,* 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, 905–817–5700. (Formerly: NOVAMANN (Ontario) Inc.). MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 651–636–7466/800–832–3244. MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950– 5295. Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Dr., Minneapolis, MN 55417, 612–725– 2088. PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350– 3515. Northwest Toxicology, a LabOne Company, 2282 South Presidents Drive, Suite C, West Valley City, UT 84120, 801–293–2300/800–322– 3361. (Formerly: LabOne, Inc., d/b/ a Northwest Toxicology; NWT Drug Testing, NorthWest Toxicology, Inc.; Northwest Drug Testing, a division of NWT Inc.). One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774. (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB PathologyToxicology Laboratory). Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, 541–687–2134. Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942. (Formerly: Centinela Hospital Airport Toxicology Laboratory). Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755– 8991/800–541–7897 x7. Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–339–0372/800–821– 3627. Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590/800–729–6432. (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 800–824–6152. (Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702–733– 7866/800–433–2750. (Formerly: Associated Pathologists Laboratories, Inc.). Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA 19403, 610–631–4600/877–642–2216. (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, 800–669–6995/847–885–2010. (Formerly: SmithKline Beecham Clinical Laboratories; International Toxicology Laboratories). Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, E:\FR\FM\02MYN1.SGM 02MYN1 Federal Register / Vol. 70, No. 83 / Monday, May 2, 2005 / Notices 818–989–2520/800–877–2520. (Formerly: SmithKline Beecham Clinical Laboratories). Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130. Sciteck Clinical Laboratories, Inc., 317 Rutledge Rd., Fletcher, NC 28732, 828–650–0409. S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505–727–6300/800–999–5227. South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x276. Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507/ 800–279–0027. Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517–364–7400. (Formerly: St. Lawrence Hospital & Healthcare System). St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405– 272–7052. Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273. Toxicology Testing Service, Inc., 5426 NW. 79th Ave., Miami, FL 33166, 305–593–2260. U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085. * The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory VerDate jul<14>2003 19:05 Apr 29, 2005 Jkt 205001 Guidelines published in the Federal Register on April 13, 2004 (69 FR 19644). After receiving DOT certification, the laboratory will be included in the monthly list of HHS certified laboratories and participate in the NLCP certification maintenance program. 22667 purposes of: (1) Observing, reviewing, and evaluating operational sites where Science and Technology products are apparent and where the systems engineering challenges are visible; (2) receiving a report from the Under Secretary for Science and Technology on how the prior year HSSTAC recommendations are being/will be Anna Marsh, implemented; (3) receiving a briefing on Executive Officer, SAMHSA. the Maritime Domain Awareness (MDA) [FR Doc. 05–8746 Filed 4–29–05; 8:45 am] Architecture; (4) touring, observing and BILLING CODE 4160–20–P evaluating DHS operational sites and facilities; and (5) receiving subcommittee reports. DEPARTMENT OF HOMELAND Specifically, the HSSTAC will receive SECURITY briefings and tours that will include information and demonstrations Office of the Secretary detailing law enforcement methods and techniques utilized to prevent terrorists [Docket No. DHS–2005–0033] from entering our nation and carrying Notice of Meeting of Homeland out catastrophic events on our air Security Science and Technology transportation system. They will Advisory Committee observe demonstrations of two databases used to identify potential AGENCY: Office of Studies and Analysis, repeat criminal offenders, non-intrusive Science and Technology Directorate, inspection equipment, evolving ‘‘older Department of Homeland Security. technology’’ (non-integrated, handheld, ACTION: Notice. etc.), and canine operations. The HSSTAC will review the results of its SUMMARY: The Homeland Security subcommittees’ activities undertaken Science and Technology Advisory since the last quarterly meeting in Committee (HSSTAC) will meet in February 2005, and discuss any closed session. proposed subcommittee DATES: May 18, 2005 and May 19, 2005. recommendations. They will receive a ADDRESSES: If you wish to submit report from the Under Secretary comments, you must do so by May 10, detailing proposed actions and actions 2005. Comments must be identified by being taken by the Directorate as a result DHS–2005–0033 and may be submitted of the recommendations contained in by one of the following methods: the HSSTAC annual report to the Under • EPA Federal Partner EDOCKET Web Secretary and Congress. Finally, they site: https://www.epa.gov/feddocket. will receive a classified briefing on Follow instructions for submitting MDA, a ‘‘global’’ program that attempts comments on the Web site. to assess any potential threat posed by • E-mail: HSSTAC@dhs.gov. Include vessels, cargo, and people involved in docket number in the subject line of the the Maritime Environment, and will message. tour the Joint Harbor Operations Center. • Fax: 202–254–6177. In accordance with section 10(d) of • Mail: Ms. Brenda Leckey, Office of the Federal Advisory Committee Act, Studies and Analysis, Science and Public Law 92–463, as amended (5 Technology Directorate, Department of U.S.C. App. 1 et seq.) and pursuant to Homeland Security, Washington, DC the authority delegated to him by the 20528. Secretary in DHS Management Directive Docket: For access to the docket to 2300, the Under Secretary for Science read background documents or and Technology has determined that comments received, go to https:// this HSSTAC meeting will address: www.epa.gov/feddocket. Classified matters of national security FOR FURTHER INFORMATION CONTACT: concern; internal administrative and Brenda Leckey, Office of Studies and personnel matters specific to committee Analysis, Science and Technology and agency operations; matters Directorate, Department of Homeland pertaining to law enforcement activity; Security, Washington, DC 20528, and matters the disclosure of which HSSTAC@dhs.gov, 202–254–5041. would be likely to frustrate significantly proposed agency actions. Accordingly, SUPPLEMENTARY INFORMATION: Notice of consistent with the provisions of 5 this meeting is given under the Federal Advisory Committee Act (FACA), Public U.S.C. 552b(c)(1), (c)(2), (c)(7), and Law 92–463, as amended (5 U.S.C. App. (c)(9)(B), the meeting will be closed to the public. 1 et seq.). The HSSTAC will meet for PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\02MYN1.SGM 02MYN1

Agencies

[Federal Register Volume 70, Number 83 (Monday, May 2, 2005)]
[Notices]
[Pages 22665-22667]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8746]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of Laboratories Which Meet Minimum Standards To 
Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
Federal agencies of the laboratories currently certified to meet the 
standards of subpart C of the Mandatory Guidelines for Federal 
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory 
Guidelines were first published in the Federal Register on April 11, 
1988 (53 FR 11970), and subsequently revised in the Federal Register on 
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on 
April 13, 2004 (69 FR 19644).
    A notice listing all currently certified laboratories is published 
in the Federal Register during the first week of each month. If any 
laboratory's certification is suspended or revoked, the laboratory will 
be omitted from subsequent lists until such time as it is restored to 
full certification under the Mandatory Guidelines.
    If any laboratory has withdrawn from the HHS National Laboratory 
Certification Program (NLCP) during the past month, it will be listed 
at the end, and will be omitted from the monthly listing thereafter.
    This notice is also available on the Internet at https://
workplace.samhsa.gov and https://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, 
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke 
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in 
accordance with Executive Order 12564 and section 503 of Public Law 
100-71. Subpart C of the Mandatory Guidelines, ``Certification of 
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets 
strict standards that laboratories must meet in order to conduct drug 
and specimen validity tests on urine specimens for Federal agencies. To 
become certified, an applicant laboratory must undergo three rounds of 
performance testing plus an on-site inspection. To maintain that

[[Page 22666]]

certification, a laboratory must participate in a quarterly performance 
testing program plus undergo periodic, on-site inspections.
    Laboratories which claim to be in the applicant stage of 
certification are not to be considered as meeting the minimum 
requirements described in the HHS Mandatory Guidelines. A laboratory 
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
    In accordance with Subpart C of the Mandatory Guidelines dated 
April 13, 2004 (69 FR 19644), the following laboratories meet the 
minimum standards to conduct drug and specimen validity tests on urine 
specimens:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-
7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 
585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, 
TN 38118, 901-794-5770/888-290-1150.
Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 
37210, 615-255-2400.
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7, 
Little Rock, AR 72205-7299, 501-202-2783, (Formerly: Forensic 
Toxicology Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215-2802, 800-
445-6917.
Diagnostic Services Inc., dba DSI, 12700 Westlinks Dr., Fort Myers, FL 
33913, 239-561-8200/800-735-5416.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281.
DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 
Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 
206-386-2661/800-898-0180, (Formerly: Laboratory of Pathology of 
Seattle, Inc., DrugProof, Division of Laboratory of Pathology of 
Seattle, Inc.).
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 
215-674-9310.
Dynacare Kasper Medical Laboratories,* 10150-102 St., Suite 200, 
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702/800-661-9876.
ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 
662-236-2609.
Express Analytical Labs, 3405 7th Ave., Suite 106, Marion, IA 52302, 
319-377-0500.
General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 
608-267-6225.
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 
504-361-8989/800-433-3823. (Formerly: Laboratory Specialists, Inc.).
LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/800-
873-8845. (Formerly: Center for Laboratory Services, a Division of 
LabOne, Inc.).
Laboratory Corporation of America Holdings, 7207 N. Gessner Rd., 
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 
08869, 908-526-2400/800-437-4986. (Formerly: Roche Biomedical 
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Dr., 
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984. (Formerly: 
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, 
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical 
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche 
Group).
Laboratory Corporation of America Holdings, 10788 Roselle St., San 
Diego, CA 92121, 800-882-7272. (Formerly: Poisonlab, Inc.).
Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042/800-233-6339. (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center).
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak 
Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734.
MAXXAM Analytics Inc.,* 6740 Campobello Road, Mississauga, ON, Canada 
L5N 2L8, 905-817-5700. (Formerly: NOVAMANN (Ontario) Inc.).
MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology 
Laboratory, 1 Veterans Dr., Minneapolis, MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
Northwest Toxicology, a LabOne Company, 2282 South Presidents Drive, 
Suite C, West Valley City, UT 84120, 801-293-2300/800-322-3361. 
(Formerly: LabOne, Inc., d/b/a Northwest Toxicology; NWT Drug Testing, 
NorthWest Toxicology, Inc.; Northwest Drug Testing, a division of NWT 
Inc.).
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, 
TX 77504, 888-747-3774. (Formerly: University of Texas Medical Branch, 
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, 
OR 97440-0972, 541-687-2134.
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942. (Formerly: Centinela Hospital Airport Toxicology 
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, 
WA 99204, 509-755-8991/800-541-7897 x7.
Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 
66210, 913-339-0372/800-821-3627.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 
30340, 770-452-1590/800-729-6432. (Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 
800-824-6152. (Moved from the Dallas location on 03/31/01; Formerly: 
SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science 
Laboratories).
Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250, Las 
Vegas, NV 89119-5412, 702-733-7866/800-433-2750. (Formerly: Associated 
Pathologists Laboratories, Inc.).
Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA 19403, 
610-631-4600/877-642-2216. (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 
60173, 800-669-6995/847-885-2010. (Formerly: SmithKline Beecham 
Clinical Laboratories; International Toxicology Laboratories).
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405,

[[Page 22667]]

818-989-2520/800-877-2520. (Formerly: SmithKline Beecham Clinical 
Laboratories).
Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, 
VA 23236, 804-378-9130.
Sciteck Clinical Laboratories, Inc., 317 Rutledge Rd., Fletcher, NC 
28732, 828-650-0409.
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 
505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x276.
Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 
1210 W. Saginaw, Lansing, MI 48915, 517-364-7400. (Formerly: St. 
Lawrence Hospital & Healthcare System).
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma 
City, OK 73101, 405-272-7052.
Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 
65203, 573-882-1273.
Toxicology Testing Service, Inc., 5426 NW. 79th Ave., Miami, FL 33166, 
305-593-2260.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., 
Fort George G. Meade, MD 20755-5235, 301-677-7085.
    * The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories was transferred to the U.S. HHS, with the HHS' NLCP 
contractor continuing to have an active role in the performance testing 
and laboratory inspection processes. Other Canadian laboratories 
wishing to be considered for the NLCP may apply directly to the NLCP 
contractor just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 13, 2004 (69 FR 19644). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS certified laboratories and participate in the 
NLCP certification maintenance program.

Anna Marsh,
Executive Officer, SAMHSA.
[FR Doc. 05-8746 Filed 4-29-05; 8:45 am]
BILLING CODE 4160-20-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.